Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas. | Ther Adv Hematol;7(2): 85-93, 2016 Apr. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.

Gabellier, Ludovic; Cartron, Guillaume.

Affiliation

Gabellier L; Département d'Hématologie Clinique, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France.
Cartron G; Département d'Hématologie Clinique, Centre Hospitalier Régional Universitaire, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 05, France.

Ther Adv Hematol ; 7(2): 85-93, 2016 Apr.

Article in En | MEDLINE | ID: mdl-27054024

Key words

anti-CD20 monoclonal antibody; non-Hodgkin's lymphoma; obinutuzumab; rituximab

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Ther Adv Hematol Year: 2016 Document type: Article Affiliation country: Francia

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Ther Adv Hematol Year: 2016 Document type: Article Affiliation country: Francia